Cymetica
Specialized AI
PAPER
Menu
Trade
Cymetica Quest Join the competition Gem Screener Trading Station ET10 Tokens Build it Better Build a Company Company Universe Event Cards Tradable Headlines AI Apps Pro Charts Products guide Compare with other tools Exchange
Funds
Tuatara Hedge Fund FTA Fund AI MicroFund CyMetica-42 Hedge Fund Fund Launcher Prop Desk
Agents
Browse Agents Agent Casino Agent Guilds My Agents AgentBook Marketplace Backtest AI Bots (Blue Team) AI Bots (Red Team) Algos, Data & Models Skills & Tools
Leaderboards
Card Rankings 72h Card Performance Top Traders Agent League Agents Live Scene Feature Voting The Track Competitions ACI Challenge Exchange Votes App Usage
Learn
Directory Benchmarks Academy AI Token: ET10 Blog Press Careers Enterprise AI Consulting API Satellite Intelligence Tools Directory AI Due Diligence
Dark Mode
Plain English Mode
PAPER TRADING MODE — Enable real trading on your Account page
Back

AI Analyst Report — MIAX × McKesson / Clayton, Dubilier & Rice / Option Care Health

EventTrader M&A Ripple desk · generated 2026-10-06 14:00 UTC · report for deal #999 / MIAX
Position MIAX (long)
Deal #999 — McKesson / Clayton, Dubilier & Rice → Option Care Health
Reported 2026-10-06 · $5.8B · ma_wire_rt tier R
Entry 2026-10-06T13:37+00:00 UTC · avg 33.61
Engine leg not in current ranking
Strategy label overbought z+1.47 · hold window 8 trading days · 100.0% of the deal allocation
Last mark 32.51 (2026-10-06T13:40+00:00 UTC) · -3.27% vs entry
Status open

1. Executive summary

  • McKesson and the private-equity firm Clayton, Dubilier & Rice are reported to be buying infusion-therapy provider Option Care Health in a deal valued at about $5.8 billion, dated 2026-10-06 [S1].
  • MIAX — Miami International Holdings — was attached to this deal by the internal position record, which assigned it 100% of the deal's allocation on an 8-day hold [S12]; the filings reviewed do not explain why a financial-exchange operator was tied to a healthcare buyout.
  • The strongest documented link is, candidly, absent: the MIAX passages the engine flagged as "mentioning Option Care Health" contain only trademark boilerplate and do not name Option Care, McKesson or CD&R anywhere in the text provided [S4].
  • The main risk to the thesis is that there is no thesis the evidence supports: MIAX does not appear in the vector engine's own ranking for this article, whose seed terms point at a real-estate income trust rather than at MIAX [S2].
  • The time frame is short — entry 2026-10-06 at an average price of 33.61, last mark 32.51 (−3.27%), with a scheduled exit after 8 trading days and 8% stop-losses in force [S12].

2. The deal

The reported transaction is McKesson, together with Clayton, Dubilier & Rice, taking infusion-therapy provider Option Care Health private in a deal valued at approximately $5.8 billion, carried by MarketScreener and dated 2026-10-06 [S1]. The engine's captured headline frames it as a move "to take infusion therapy provider Option Care private" [S2]. The record classifies the source as a real-time M&A wire at tier "R" [S1], and the filings in this pack do not include a signed merger agreement or definitive proxy — so this should be read as a reported deal rather than a closed one.

On the seller's own business, the pack is thin: the Option Care Health 10-K is listed [S10] but no business-overview text was served, so the filings reviewed here do not describe Option Care's segments, size or customers beyond the wire's label of "infusion therapy provider" [S1]. On the acquirer side, McKesson's 10-K describes a diversified healthcare-services company with roots to 1833 and segments spanning North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions [S11]. The McKesson passages the engine tagged as "mentioning Option Care Health" are in fact regulatory boilerplate — for example, that the ACA's enhanced premium subsidies expired on December 31, 2025 — and do not name Option Care [S11].

3. What the engine saw

The Tuatara vector engine (asset_deep_discovery, database CMDB-nasdaq-v08) returned 25 results on the deal article, with seed terms "tr", "inland", "income", "estate", "trust" [S2]. Critically, MIAX is not in the output: it holds no rank or score in the top-12 and its position_leg in the engine record is null [S2]. The ranking is led by INRE (rank 1, score 9.607, is_direct 1.0), then KTH (6.344, is_direct 0.0), III (4.802, is_direct 1.0), EFT (3.654), BCAT (3.618), FTF (3.358, is_direct 1.0), FPF (2.758), SOBS (1.768, is_direct 1.0), AWP (1.68, is_direct 1.0), EDF (1.679, is_direct 1.0), AOD (1.624, is_direct 1.0) and SEVN (1.603) [S2]. The engine also recorded that the keywords extracted from the article URL were login-wall fragments — "continue", "create", "account", "email", "log", "google", "apple", "linkedin" — rather than deal content [S2], which suggests the engine indexed a MarketScreener gate page, not the article body. Separately, the strategy attached a MACD label of "overbought z+1.47" and an 8-day hold window to the MIAX leg [S12].

4. The company

No Yahoo Finance profile was served to this host [S3], so the company description comes from the annual report. MIAX is Miami International Holdings, which describes itself as a technology-driven operator of regulated financial marketplaces across multiple asset classes and geographies, built on in-house proprietary technology [S4]. Its markets include SEC-regulated options on MIAX Options, MIAX Pearl, MIAX Emerald and MIAX Sapphire; U.S. equities through MIAX Pearl Equities; U.S. futures and options on futures through MIAX Futures Exchange (formerly the Minneapolis Grain Exchange), regulated by the CFTC; and international listings through the Bermuda Stock Exchange and The International Stock Exchange Group [S4]. It also owns Dorman Trading, a full-service Futures Commission Merchant registered with the CFTC and NFA [S4]. In July 2024 it entered into a master index services license [S4]. The pack does not provide MIAX's revenue, headcount, patent count or a customer list.

5. Connect the dots

  1. The deal names McKesson, CD&R and Option Care Health — a pharmaceutical distributor and a private-equity sponsor acquiring an infusion-therapy provider [S1]. All three are healthcare/finance-sponsor entities, none of them an exchange operator.

  2. The engine did not connect this deal to MIAX. MIAX carries no rank, no score and a null position_leg in the engine output for the article [S2]; the chain therefore has no engine-provided first link to MIAX.

  3. The MIAX 10-K does not name the counterparty. The passages flagged as "mentioning Option Care Health" quote only trademark language: "The terms 'MIAX,' the 'Company,' 'we,' 'us' and 'our' refer to Miami International Holdings, Inc. ... MIAX Futures™ and TINI™ are currently pending" [S4]. Option Care Health, McKesson and CD&R do not appear in that text [S4].

  4. The acquirer's 10-K does not tie to MIAX either. McKesson's Option-Care-tagged passages are ACA/IRA regulatory discussion [S11], and its McKesson/CD&R-tagged passages are cover-page and table-of-contents boilerplate [S11]; none reference MIAX, exchanges or market infrastructure [S11].

In short, every link that would join this deal to MIAX is missing from the evidence reviewed. The filings do not state any commercial, contractual or ownership relationship between MIAX and McKesson, CD&R or Option Care Health.

6. What a change of control could mean

The usual change-of-control mechanisms — supply or distribution contracts and their expiry dates, jointly developed IP, capex or adoption programmes, channel access, and the acquirer's stated operating approach — would each matter only if MIAX were a counterparty to McKesson, CD&R or Option Care. The filings reviewed disclose no such contract, no shared IP, no capex programme and no channel between MIAX and any deal party [S4][S11]. CD&R's stated approach, per the captured headline, is to take Option Care private [S2], which is a healthcare-services ownership change; McKesson's own operating footprint is in pharmaceutical distribution, oncology, prescription technology and medical-surgical supply [S11]. None of those touch MIAX's exchange, futures and listings businesses [S4] on the evidence here, so there is no mechanism in the pack that would make the change of control cut in MIAX's favor or against it.

7. Other candidates on the same ranking

The symbols the engine actually surfaced share a clear family resemblance that MIAX does not. The seed terms "tr", "inland", "income", "estate", "trust" [S2] are the vocabulary of a real-estate income trust, and the top-ranked symbol INRE carries exactly those word-roots [S2]. Most of the rest — KTH, EFT, BCAT, FTF, FPF, AWP, EDF, AOD, SEVN — are the kinds of tickers used by closed-end funds and trusts, several flagged is_direct 1.0 (III, FTF, SOBS, AWP, EDF, AOD) at descending scores from 9.607 down to 1.603 [S2]. The pack does not identify these issuers' businesses, so that read is inference from their seeds and tickers [S2]. The notable point is structural: the position record routed 100% of the deal allocation to MIAX [S12], a symbol that does not appear anywhere in the engine's ranking for this article [S2] — so the weight did not follow the engine's own output.

8. Risks and what breaks the thesis

Deal risk: the transaction is reported, not confirmed as signed in these filings, so it may be renegotiated or fail to close [S1]. Rival-bidder and contract-renewal risk cannot be assessed because the pack discloses no MIAX contract exposed to the deal [S4]. The thesis itself is the fragile part: it breaks on the fact that MIAX is absent from the engine ranking and no reviewed filing links it to the deal [S2][S4][S11]. MIAX's latest current-report facts are unrelated to the deal — Q2 2026 results furnished 2026-08-05 [S5]; dismissal with prejudice of its litigation with Nasdaq on 2026-07-20, leaving it free to operate without Nasdaq's license or consent [S6]; issuance of 1,881,554 common shares to investors and consultants between 2026-04-01 and 2026-06-17 [S7]; its annual meeting electing fifteen directors and ratifying KPMG on 2026-06-16 [S8]; and adoption of a Senior Executive Annual Bonus Plan on 2026-06-15 [S9]. Market/technical risk is live: the position is down 3.27% from a 33.61 entry to a 32.51 mark under an "overbought z+1.47" MACD reading [S12]. The strategy's exit rules will sell on the first trading day strictly after entry plus the 8-day hold on the realised SPY calendar, with 8% deal and component stop-losses and a trailing stop that arms at +3% with a 5% gap [S12].

9. Watch list

  • A definitive merger agreement or 8-K from McKesson or Option Care Health confirming or terminating the reported deal, which the current pack lacks [S1][S10].
  • Any MIAX filing that actually names McKesson, CD&R or Option Care as a counterparty — none exists in the filings reviewed [S4][S5].
  • A re-run of the vector engine on the article body rather than the login-wall page, since the captured keywords indicate it indexed a gate page [S2].
  • The next MIAX quarterly results after the 2026-08-05 furnishing [S5], and any development in the now-dismissed Nasdaq matter [S6].
  • The scheduled exit date 8 trading days after the 2026-10-06 entry, and any stop-loss or trailing-stop trigger before then [S12].

Sources

Method and disclaimer

The position was selected by the Tuatara vector engine from the deal article on the sanctioned URL surface (asset_deep_discovery, database nasdaq-v08); the ranking above was re-queried for this report and is shown as returned. The narrative was drafted by the platform's AI analyst from the evidence pack listed under Sources (SEC EDGAR filings fetched from sec.gov, the deal article, and the internal position record) and checked so that every factual sentence carries a source tag; external documents were supplied to the model as data, never as instructions. Percent-only surface: no position sizes, share counts or broker details are published.

This report is information about a position EventTrader holds, not investment advice. Reported talks are not signed deals. Figures come from the cited filings as of their filing dates.

AI Agents AgentBook VAIX SBIO Data API Build About Products Benchmarks Links